Stockscreener 앱 받기
11.02
0.09%
-0.010
시간 외 거래:
10.94
-0.08
-0.73%
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - Defense World
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Institutional owners may consider drastic measures as Keros Therapeutics, Inc.'s (NASDAQ:KROS) recent US$55m drop adds to long-term losses - Simply Wall St
Research Analysts Issue Forecasts for KROS FY2028 Earnings - MarketBeat
There is no way Keros Therapeutics Inc (KROS) can keep these numbers up - SETE News
Examining the Potential Price Growth of Keros Therapeutics Inc (KROS) - Knox Daily
Leerink Partnrs Has Positive Outlook of KROS FY2028 Earnings - Defense World
(KROS) Proactive Strategies - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KROS Shares Experience Surge in Value - Knox Daily
24,493 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by SG Americas Securities LLC - MarketBeat
Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily
An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News
SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Markets Insider
KROS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Keros Therapeutics, Inc. and Encourages Investors to Contact the Firm - ACCESS Newswire
When (KROS) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Markets Insider
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on ... - The Bakersfield Californian
Keros Therapeutics seals $200M deal with Takeda - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald - Defense World
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS) - Business Wire
Keros Therapeutics seals $200M deal with Takeda By Investing.com - Investing.com Australia
Cantor Fitzgerald Estimates KROS FY2025 Earnings - MarketBeat
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - GlobeNewswire
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) - MSN
0.27%
3.05%
자본화:
|
볼륨(24시간):